Afrezza

What Is Afrezza?

Afrezza (insulin human) Inhalation Powder is the only FDA-approved ultra rapid-acting inhaled insulin for adults with Type 1 or Type 2 diabetes. Unlike traditional injectable insulins, Afrezza is breathed in through the mouth using a small, whistle-sized inhaler at the beginning of a meal. It uses MannKind's proprietary Technosphere technology to deliver insulin directly to the lungs, where it is rapidly absorbed into the bloodstream. Afrezza was FDA-approved in 2014 and is manufactured by MannKind Corporation.

Afrezza is used as a mealtime (prandial) insulin to control blood sugar spikes after eating. For Type 1 diabetes patients, it must be used in combination with a long-acting basal insulin. It is not a substitute for long-acting insulin and should not be used to treat diabetic ketoacidosis.